Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Different neoadjuvant therapies have been proposed to improve immunotherapy for cancer treatment. Here, the authors perform a phase Ib clinical trial where an agonist OX40 antibody provided prior to surgery is well tolerated and increases proliferation and activation of tumor antigen-specific T cell...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K. Frye, Eric Tran, Venkatesh Rajamanickam, Shu-Ching Chang, Yoshinobu Koguchi, Carlo B. Bifulco, Brady Bernard, Rom S. Leidner, Brendan D. Curti, Bernard A. Fox, Walter J. Urba, R. Bryan Bell, Andrew D. Weinberg
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/e0c32b2dd76c42039a82409b6dfffcd3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e0c32b2dd76c42039a82409b6dfffcd3
record_format	dspace
spelling	oai:doaj.org-article:e0c32b2dd76c42039a82409b6dfffcd32021-12-02T14:03:40ZNeoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells10.1038/s41467-021-21383-12041-1723https://doaj.org/article/e0c32b2dd76c42039a82409b6dfffcd32021-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-21383-1https://doaj.org/toc/2041-1723Different neoadjuvant therapies have been proposed to improve immunotherapy for cancer treatment. Here, the authors perform a phase Ib clinical trial where an agonist OX40 antibody provided prior to surgery is well tolerated and increases proliferation and activation of tumor antigen-specific T cells in head and neck cancer patients.Rebekka DuhenCarmen Ballesteros-MerinoAlexandra K. FryeEric TranVenkatesh RajamanickamShu-Ching ChangYoshinobu KoguchiCarlo B. BifulcoBrady BernardRom S. LeidnerBrendan D. CurtiBernard A. FoxWalter J. UrbaR. Bryan BellAndrew D. WeinbergNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Rebekka Duhen Carmen Ballesteros-Merino Alexandra K. Frye Eric Tran Venkatesh Rajamanickam Shu-Ching Chang Yoshinobu Koguchi Carlo B. Bifulco Brady Bernard Rom S. Leidner Brendan D. Curti Bernard A. Fox Walter J. Urba R. Bryan Bell Andrew D. Weinberg Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
description	Different neoadjuvant therapies have been proposed to improve immunotherapy for cancer treatment. Here, the authors perform a phase Ib clinical trial where an agonist OX40 antibody provided prior to surgery is well tolerated and increases proliferation and activation of tumor antigen-specific T cells in head and neck cancer patients.
format	article
author	Rebekka Duhen Carmen Ballesteros-Merino Alexandra K. Frye Eric Tran Venkatesh Rajamanickam Shu-Ching Chang Yoshinobu Koguchi Carlo B. Bifulco Brady Bernard Rom S. Leidner Brendan D. Curti Bernard A. Fox Walter J. Urba R. Bryan Bell Andrew D. Weinberg
author_facet	Rebekka Duhen Carmen Ballesteros-Merino Alexandra K. Frye Eric Tran Venkatesh Rajamanickam Shu-Ching Chang Yoshinobu Koguchi Carlo B. Bifulco Brady Bernard Rom S. Leidner Brendan D. Curti Bernard A. Fox Walter J. Urba R. Bryan Bell Andrew D. Weinberg
author_sort	Rebekka Duhen
title	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
title_short	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
title_full	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
title_fullStr	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
title_full_unstemmed	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
title_sort	neoadjuvant anti-ox40 (medi6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating t cells
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e0c32b2dd76c42039a82409b6dfffcd3
work_keys_str_mv	AT rebekkaduhen neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT carmenballesterosmerino neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT alexandrakfrye neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT erictran neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT venkateshrajamanickam neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT shuchingchang neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT yoshinobukoguchi neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT carlobbifulco neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT bradybernard neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT romsleidner neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT brendandcurti neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT bernardafox neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT walterjurba neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT rbryanbell neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells AT andrewdweinberg neoadjuvantantiox40medi6469therapyinpatientswithheadandnecksquamouscellcarcinomaactivatesandexpandsantigenspecifictumorinfiltratingtcells
_version_	1718392114218270720

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Ejemplares similares